Otsuka Pharmaceutical Obtains Exclusive Rights Across Asia-pacific Region For Ionis Pharmaceuticals' Donidalorsen For Hereditary Angioedema, Ionis Will Receive $20M Upfront Payment And Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Otsuka Pharmaceutical has obtained exclusive rights across the Asia-Pacific region for Ionis Pharmaceuticals' donidalorsen for hereditary angioedema. Ionis will receive a $20M upfront payment and milestone payments. Ionis will handle primary development, while Otsuka will manage territory-specific development, regulatory filings, and commercialization in the Asia-Pacific region and Europe.
June 18, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals has entered into a partnership with Otsuka Pharmaceutical, granting Otsuka exclusive rights to donidalorsen in the Asia-Pacific region. Ionis will receive a $20M upfront payment and milestone payments, while maintaining primary development responsibilities.
The partnership with Otsuka provides Ionis with immediate revenue through the $20M upfront payment and potential future milestone payments. This deal also allows Ionis to focus on primary development while leveraging Otsuka's expertise in the Asia-Pacific region, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100